Biotech Values

[DewDiligence]

Credit Suisse says NVS has the best 2011-2012 growth prospects in Big Pharma (#msg-57458464), which is not exactly an epiphany (#msg-51791410), although Morningstar thought it was (#msg-57376875) :- )

While Wall Street has focused its attention on such NVS products as Gilenya, generic Lovenox is sufficiently consequential to be moving the needle even for a company as large as NVS that is keeping only 55% of the profits.